Aromatase deficiency is a rare autosomal recessive disorder caused by biallelic CYP19A1 loss-of-function variants. Deficient aromatase activity impairs conversion of androgen precursors to estrogens, producing congenital estrogen deficiency with androgen excess. The phenotype is sex- and age- dependent: 46,XX individuals can present with maternal antenatal virilization, ambiguous genitalia, hypergonadotropic hypogonadism, poor pubertal development, primary amenorrhea, and ovarian cysts, while 46,XY individuals can present later with tall stature, delayed skeletal maturation, osteoporosis, and metabolic impairment.
Ask a research question about Aromatase Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Aromatase Deficiency
creation_date: "2025-12-04T16:57:31Z"
updated_date: "2026-05-20T10:46:54Z"
description: >-
Aromatase deficiency is a rare autosomal recessive disorder caused by
biallelic CYP19A1 loss-of-function variants. Deficient aromatase activity
impairs conversion of androgen precursors to estrogens, producing congenital
estrogen deficiency with androgen excess. The phenotype is sex- and age-
dependent: 46,XX individuals can present with maternal antenatal virilization,
ambiguous genitalia, hypergonadotropic hypogonadism, poor pubertal
development, primary amenorrhea, and ovarian cysts, while 46,XY individuals
can present later with tall stature, delayed skeletal maturation,
osteoporosis, and metabolic impairment.
category: Mendelian
parents:
- Endocrine Disorder
- Inborn Error of Metabolism
disease_term:
preferred_term: aromatase deficiency
description: >-
A rare autosomal recessive disorder caused by CYP19A1 mutations resulting
in inability to convert androgens to estrogens.
term:
id: MONDO:0013301
label: aromatase deficiency
prevalence:
- population: Global
percentage: Rare
evidence:
- reference: PMID:23748068
reference_title: "Aromatase deficiency, a rare syndrome: case report."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Aromatase deficiency (AD) is a rare autosomal recessive inheritance syndrome. Its worldwide incidence is unknown, and there are few case reports in the literature.
explanation: >-
The case-report abstract explicitly describes aromatase deficiency as rare
and states that worldwide incidence is unknown.
progression:
- phase: Onset
age_range: Fetal life-adulthood
evidence:
- reference: PMID:19844120
reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Placental aromatization of androgens protects the female fetus against the virilizing action of fetal androgens. After birth, the dual effect of aromatase deficiency, excessive androgens, and insufficient estrogens is responsible for a variable clinical picture.
explanation: >-
Review-level evidence supports prenatal and postnatal manifestations from
the same androgen-excess/estrogen-deficiency mechanism.
- reference: PMID:24705274
reference_title: "Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
To date over 20 subjects have been reported with aromatase deficiency which may manifest during fetal life with maternal virilization and virilization of the external genitalia of a female fetus due to low aromatase activity in the steroid metabolizing fetal-placental unit and thus high androgen levels.
explanation: >-
Human case-report literature supports fetal-life manifestations caused by
low aromatase activity in the fetal-placental unit.
pathophysiology:
- name: CYP19A1 Loss-of-Function and Aromatase Deficiency
description: >-
Biallelic loss-of-function variants in CYP19A1 reduce or abolish aromatase
activity. Aromatase normally catalyzes androgen-to-estrogen conversion in
the placenta, gonads, adipose tissue, and other estrogen-producing tissues.
role: Primary
genes:
- preferred_term: CYP19A1
term:
id: hgnc:2594
label: CYP19A1
cell_types:
- preferred_term: granulosa cell
description: Ovarian site of aromatase expression for estrogen synthesis.
term:
id: CL:0000501
label: granulosa cell
- preferred_term: trophoblast cell
description: Placental aromatase site; loss causes maternal and fetal virilization.
term:
id: CL:0000351
label: trophoblast cell
- preferred_term: Leydig cell
description: Testicular androgen source; aromatization affects systemic hormone balance.
term:
id: CL:0000178
label: Leydig cell
- preferred_term: adipocyte
description: Peripheral aromatase expression site contributing to local estrogen production.
term:
id: CL:0000136
label: adipocyte
molecular_functions:
- preferred_term: aromatase activity
modifier: DECREASED
term:
id: GO:0070330
label: aromatase activity
biological_processes:
- preferred_term: steroid biosynthetic process
modifier: ABNORMAL
term:
id: GO:0006694
label: steroid biosynthetic process
- preferred_term: estrogen biosynthetic process
modifier: DECREASED
term:
id: GO:0006703
label: estrogen biosynthetic process
- preferred_term: androgen metabolic process
modifier: ABNORMAL
term:
id: GO:0008209
label: androgen metabolic process
chemical_entities:
- preferred_term: estradiol
modifier: DECREASED
term:
id: CHEBI:23965
label: estradiol
- preferred_term: testosterone
modifier: INCREASED
term:
id: CHEBI:17347
label: testosterone
locations:
- preferred_term: ovary
description: Site of granulosa aromatase; ovarian development and fertility are affected.
term:
id: UBERON:0000992
label: ovary
- preferred_term: placenta
description: Crucial fetal-placental estrogen-production site.
term:
id: UBERON:0001987
label: placenta
- preferred_term: testis
description: Androgen source; 46,XY genital phenotype is often milder than 46,XX.
term:
id: UBERON:0000473
label: testis
- preferred_term: adipose tissue
description: Peripheral aromatization site.
term:
id: UBERON:0001013
label: adipose tissue
evidence:
- reference: PMID:35837780
reference_title: "Aromatase deficiency caused by mutation of CYP19A1 gene: A case report."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Aromatase deficiency (AD) is a rare autosomal recessive genetic disease caused by loss-of-function mutations in aromatase gene (CYP19A1), leading to congenital estrogen deficiency syndrome.
explanation: >-
Directly supports biallelic CYP19A1 loss of function as the proximal
cause of congenital estrogen deficiency.
- reference: PMID:24705274
reference_title: "Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
P450 aromatase (CYP19A1) is essential for the biosynthesis of estrogens from androgen precursors. Mutations in the coding region of CYP19A1 lead to autosomal recessive aromatase deficiency.
explanation: >-
Establishes CYP19A1 aromatase as the enzyme required for estrogen
biosynthesis from androgen precursors.
- reference: PMID:14968547
reference_title: "[Aromatase deficiency]."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Aromatase, a key enzyme in estrogen synthesis, is tissue-specifically regulated in various tissues and plays an important role through endocrine and intracrine estrogen production in various physiological functions.
explanation: >-
Review-level evidence supports aromatase as a tissue-regulated enzyme
required for endocrine and intracrine estrogen production.
downstream:
- target: Estrogen Deficiency and Androgen Excess
description: >-
Reduced aromatase activity blocks androgen-to-estrogen conversion, lowering
estrogen synthesis while leaving androgen precursors relatively excessive.
causal_link_type: DIRECT
evidence:
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated.
explanation: >-
Directly links inactivating aromatase variants to absent estrogen
synthesis and normal-to-elevated testosterone.
- name: Estrogen Deficiency and Androgen Excess
description: >-
Loss of aromatase causes systemic estrogen deficiency and relative androgen
excess. This disrupts genital differentiation, puberty, gonadotropin
feedback, skeletal maturation, bone mass accrual, and metabolic regulation.
biological_processes:
- preferred_term: estrogen receptor signaling pathway
modifier: DECREASED
term:
id: GO:0030520
label: estrogen receptor signaling pathway
- preferred_term: gonadotropin secretion
modifier: INCREASED
term:
id: GO:0032274
label: gonadotropin secretion
chemical_entities:
- preferred_term: estradiol
modifier: DECREASED
term:
id: CHEBI:23965
label: estradiol
- preferred_term: testosterone
modifier: INCREASED
term:
id: CHEBI:17347
label: testosterone
locations:
- preferred_term: uterus
description: Estrogen-dependent organ; hypoplasia and poor endometrial development may occur.
term:
id: UBERON:0000995
label: uterus
- preferred_term: brain
description: Central estrogen actions regulate hypothalamic-pituitary-gonadal feedback.
term:
id: UBERON:0000955
label: brain
evidence:
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated.
explanation: >-
Summarizes the core endocrine state: absent estrogen synthesis with
gonadotropins and testosterone ranging from normal to elevated.
- reference: PMID:19844120
reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
After birth, the dual effect of aromatase deficiency, excessive androgens, and insufficient estrogens is responsible for a variable clinical picture.
explanation: >-
Supports the combined estrogen-deficiency and androgen-excess mechanism.
downstream:
- target: Maternal Antenatal Virilization
description: >-
Failure of fetal-placental aromatization exposes the pregnant mother to
excess androgens, producing antenatal virilization during affected
pregnancies.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Excess androgens in the fetal-placental unit during pregnancy.
evidence:
- reference: PMID:40321354
reference_title: "Aromatase deficiency due to novel CYP19A1 mutation: a rare cause of maternal and fetal virilization."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This enzyme protects the fetus and mother from excess androgens by converting them into estrogen.
explanation: >-
The case-report abstract directly supports maternal androgen exposure
when CYP19A1 aromatization is deficient.
- target: Gonadotropin Feedback and Reproductive Development Disruption
description: >-
Low estrogen weakens reproductive-tissue maturation and negative feedback
on the hypothalamic-pituitary-gonadal axis.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Reduced estrogen receptor signaling in reproductive tissues and pituitary feedback circuits.
evidence:
- reference: PMID:11305285
reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization.
explanation: >-
Review-level human evidence links aromatase deficiency to pubertal
gonadotropin and reproductive-development disruption.
- target: Impaired Skeletal Maturation and Bone Remodeling
description: >-
Estrogen deficiency delays epiphyseal closure and impairs bone mineral
accrual, causing delayed skeletal maturation and low bone mass.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Reduced estrogen signaling in growth plate and bone remodeling compartments.
evidence:
- reference: PMID:21874760
reference_title: "Aromatase activity and bone loss."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Several lines of clinical and experimental evidence now clearly indicate that aromatase activity and estrogen production are necessary for longitudinal bone growth, attainment of peak bone mass, the pubertal growth spurt, epiphyseal closure, and normal bone remodeling in young individuals.
explanation: >-
Supports aromatase-derived estrogen as necessary for skeletal growth,
epiphyseal closure, and bone remodeling.
- target: Metabolic Effects of Estrogen Deficiency
description: >-
Estrogen deficiency can affect glucose-insulin physiology and broader
metabolic regulation, although the precise tissue mechanisms remain less
resolved than the reproductive and skeletal manifestations.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
intermediate_mechanisms:
- Estrogen-dependent regulation of glucose metabolism and adipose/gonadal signaling.
evidence:
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
These phenotypes suggest the physiological role of estrogens on the skeleton, on pituitary function, on the reproductive system, on glucose metabolism, being the precise mechanism on each of these functions not yet known in detail.
explanation: >-
The review explicitly names glucose metabolism while noting that precise
mechanisms are not fully resolved.
- name: Gonadotropin Feedback and Reproductive Development Disruption
description: >-
Insufficient estrogen signaling disrupts pubertal maturation and removes
normal gonadotropin feedback, while androgen excess drives virilization in
46,XX individuals. Elevated FSH and ovarian cysts are frequent diagnostic
clues in 46,XX aromatase deficiency.
cell_types:
- preferred_term: granulosa cell
term:
id: CL:0000501
label: granulosa cell
biological_processes:
- preferred_term: gonadotropin secretion
modifier: INCREASED
term:
id: GO:0032274
label: gonadotropin secretion
- preferred_term: sex differentiation
modifier: ABNORMAL
term:
id: GO:0007548
label: sex differentiation
evidence:
- reference: PMID:11305285
reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It gives rise to ambiguous genitalia in 46,XX individuals. At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization.
explanation: >-
Supports 46,XX genital, gonadotropin, and pubertal manifestations.
- reference: PMID:32623730
reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30).
explanation: >-
Case series plus systematic review provides frequency counts for 46,XX
reproductive and hormonal manifestations.
downstream:
- target: Ambiguous Genitalia
description: >-
Prenatal androgen excess in 46,XX fetuses produces virilized or ambiguous
external genitalia.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Fetal-placental aromatase deficiency and high androgen exposure.
evidence:
- reference: PMID:24705274
reference_title: "Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
aromatase deficiency which may manifest during fetal life with maternal virilization and virilization of the external genitalia of a female fetus due to low aromatase activity in the steroid metabolizing fetal-placental unit and thus high androgen levels.
explanation: >-
Directly supports low fetal-placental aromatase activity causing 46,XX
external genital virilization.
- target: Clitoromegaly
description: >-
Clitoral enlargement is a specific manifestation of 46,XX prenatal and
postnatal androgen excess.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Androgen-mediated virilization of 46,XX external genitalia.
evidence:
- reference: PMID:24482950
reference_title: "Aromatase deficiency: an unusual cause for primary amenorrhea with virilization."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "She lacked feminine secondary sexual characters, had eunuchoid body habitus and prominent clitoromegaly."
explanation: >-
A human case report supports clitoromegaly as part of the virilized
46,XX phenotype.
- target: Hypergonadotropic Hypogonadism
description: >-
Low estrogen feedback contributes to elevated gonadotropins with impaired
gonadal function.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Loss of estrogen negative feedback on the hypothalamic-pituitary-gonadal axis.
evidence:
- reference: PMID:11305285
reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization."
explanation: >-
Directly supports hypergonadotropic hypogonadism in pubertal affected
girls.
- target: Delayed Puberty
description: >-
Estrogen insufficiency impairs normal pubertal development and secondary
sexual-characteristic development.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Insufficient estrogen-dependent pubertal maturation.
evidence:
- reference: PMID:19844120
reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In pubertal girls, there is poor sexual development and abnormal virilization."
explanation: >-
Supports impaired pubertal development in affected girls.
- target: Primary Amenorrhea
description: >-
Estrogen deficiency prevents normal endometrial and pubertal maturation,
causing primary amenorrhea in affected 46,XX individuals.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Failure of estrogen-dependent uterine and pubertal maturation.
evidence:
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At puberty they show primary amenorrhea, no breast development, worsening of the virilization and the absence of growth spurt."
explanation: >-
Directly supports primary amenorrhea at puberty.
- target: Polycystic Ovaries
description: >-
Elevated gonadotropins and ovarian androgens promote ovarian cyst
formation in 46,XX aromatase deficiency.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Elevated ovarian androgens and gonadotropins.
evidence:
- reference: PMID:19844120
reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In prepubertal aromatase deficient girls, high levels of ovarian androgens and gonadotropins facilitate the formation of ovarian cysts."
explanation: >-
Directly links androgen and gonadotropin excess to ovarian cyst
formation.
- name: Impaired Skeletal Maturation and Bone Remodeling
description: >-
Estrogen deficiency delays epiphyseal closure and skeletal maturation,
extends linear growth, and impairs attainment of peak bone mass, producing
tall stature, unfused epiphyses, delayed bone age, osteopenia, and
osteoporosis.
cell_types:
- preferred_term: osteoblast
term:
id: CL:0000062
label: osteoblast
- preferred_term: osteoclast
term:
id: CL:0000092
label: osteoclast
biological_processes:
- preferred_term: bone remodeling
modifier: ABNORMAL
term:
id: GO:0046849
label: bone remodeling
- preferred_term: endochondral ossification
modifier: ABNORMAL
term:
id: GO:0001958
label: endochondral ossification
locations:
- preferred_term: bone tissue
term:
id: UBERON:0002481
label: bone tissue
evidence:
- reference: PMID:21874760
reference_title: "Aromatase activity and bone loss."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Several lines of clinical and experimental evidence now clearly indicate that aromatase activity and estrogen production are necessary for longitudinal bone growth, attainment of peak bone mass, the pubertal growth spurt, epiphyseal closure, and normal bone remodeling in young individuals.
explanation: >-
Supports the skeletal maturation and bone-remodeling consequences of
aromatase/estrogen deficiency.
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The clinical phenotype in the male affected subjects comprises tall stature, persistent linear growth and delayed bone age, osteopenia/osteoporosis, eunuchoid body proportion, different degrees of glucose-insulin and of fertility impairment.
explanation: >-
Summarizes the skeletal phenotype in aromatase-deficient males.
downstream:
- target: Delayed Skeletal Maturation
description: >-
Lack of estrogen-mediated epiphyseal maturation delays bone age.
causal_link_type: DIRECT
evidence:
- reference: PMID:32623730
reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
explanation: >-
Supports delayed bone age as a common skeletal manifestation in 46,XX
aromatase deficiency.
- target: Tall Stature
description: >-
Delayed epiphyseal closure permits persistent linear growth into
adulthood, particularly in 46,XY affected individuals.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Persistent growth plate activity from lack of estrogen-mediated epiphyseal closure.
evidence:
- reference: PMID:11305285
reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "These men are extremely tall and have eunuchoid proportions with continued linear growth into adulthood, lack of epiphyseal closure, and osteoporosis due to estrogen deficiency."
explanation: >-
Directly links estrogen deficiency to tall stature and persistent growth
in 46,XY affected individuals.
- target: Osteoporosis
description: >-
Impaired estrogen-dependent bone remodeling and peak bone mass accrual
cause osteopenia or osteoporosis.
causal_link_type: DIRECT
evidence:
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The clinical phenotype in the male affected subjects comprises tall stature, persistent linear growth and delayed bone age, osteopenia/osteoporosis, eunuchoid body proportion, different degrees of glucose-insulin and of fertility impairment.
explanation: >-
Directly supports osteopenia/osteoporosis in aromatase deficiency.
- name: Metabolic Effects of Estrogen Deficiency
description: >-
Aromatase-deficient individuals can show abnormalities of glucose-insulin
physiology. The clinical literature supports metabolic involvement, but the
precise intermediates between congenital estrogen deficiency and insulin
resistance remain incompletely defined.
cell_types:
- preferred_term: adipocyte
term:
id: CL:0000136
label: adipocyte
biological_processes:
- preferred_term: glucose homeostasis
modifier: ABNORMAL
term:
id: GO:0042593
label: glucose homeostasis
- preferred_term: insulin receptor signaling pathway
modifier: ABNORMAL
term:
id: GO:0008286
label: insulin receptor signaling pathway
locations:
- preferred_term: adipose tissue
term:
id: UBERON:0001013
label: adipose tissue
evidence:
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "These phenotypes suggest the physiological role of estrogens on the skeleton, on pituitary function, on the reproductive system, on glucose metabolism, being the precise mechanism on each of these functions not yet known in detail."
explanation: >-
Review-level evidence supports glucose-metabolism involvement while
acknowledging unresolved intermediates.
- reference: PMID:19844120
reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Insulin sensitivity may be abnormal in both men and women."
explanation: >-
Supports insulin-sensitivity abnormality across sexes.
downstream:
- target: Insulin Resistance
description: >-
Estrogen-deficiency effects on glucose metabolism can manifest as reduced
insulin sensitivity.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
intermediate_mechanisms:
- Unresolved estrogen-dependent glucose-metabolism pathways.
evidence:
- reference: PMID:19844120
reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Insulin sensitivity may be abnormal in both men and women."
explanation: >-
Supports insulin-sensitivity abnormality as a metabolic manifestation of
aromatase deficiency.
phenotypes:
- category: Reproductive
name: Ambiguous Genitalia
description: >-
Virilized or atypical external genitalia in 46,XX individuals caused by
prenatal androgen excess when placental/fetal aromatization is deficient.
frequency: VERY_FREQUENT
diagnostic: true
notes: In 46,XX individuals.
phenotype_term:
preferred_term: Ambiguous genitalia
term:
id: HP:0000062
label: Ambiguous genitalia
evidence:
- reference: PMID:32623730
reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
explanation: >-
Systematic review count supports ambiguous genitalia as very frequent in
genetically confirmed 46,XX aromatase deficiency.
- category: Reproductive
name: Maternal Antenatal Virilization
description: >-
Virilization of the pregnant mother can occur when the fetal-placental unit
cannot aromatize androgen precursors to estrogens, leading to excess
androgen exposure during affected pregnancies.
frequency: FREQUENT
notes: Maternal manifestation during pregnancy with an affected fetus.
evidence:
- reference: PMID:32623730
reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
explanation: >-
The systematic review count supports maternal antenatal virilization as a
frequent presentation associated with aromatase deficiency pregnancies.
- reference: PMID:40321354
reference_title: "Aromatase deficiency due to novel CYP19A1 mutation: a rare cause of maternal and fetal virilization."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A 10-day-old newborn presented with atypical genitalia and a history of maternal virilization during pregnancy.
explanation: >-
Case-report evidence documents maternal virilization during pregnancy in
an infant with genetically confirmed aromatase deficiency.
- category: Reproductive
name: Clitoromegaly
description: Enlarged clitoris due to androgen excess in 46,XX individuals.
notes: Component of 46,XX virilization.
phenotype_term:
preferred_term: Clitoral hypertrophy
term:
id: HP:0008665
label: Clitoral hypertrophy
evidence:
- reference: PMID:24482950
reference_title: "Aromatase deficiency: an unusual cause for primary amenorrhea with virilization."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "She lacked feminine secondary sexual characters, had eunuchoid body habitus and prominent clitoromegaly."
explanation: >-
Human case report directly supports prominent clitoromegaly in a 46,XX
affected individual.
- category: Reproductive
name: Delayed Puberty
description: >-
Poor or delayed development of secondary sexual characteristics due to
estrogen deficiency.
diagnostic: true
phenotype_term:
preferred_term: Delayed puberty
term:
id: HP:0000823
label: Delayed puberty
evidence:
- reference: PMID:11305285
reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization."
explanation: >-
Supports pubertal failure/poor pubertal development in 46,XX individuals.
- category: Reproductive
name: Hypergonadotropic Hypogonadism
description: >-
Elevated gonadotropin levels with inadequate gonadal function due to loss of
estrogen feedback and impaired reproductive maturation.
diagnostic: true
phenotype_term:
preferred_term: Hypergonadotropic hypogonadism
term:
id: HP:0000815
label: Hypergonadotropic hypogonadism
evidence:
- reference: PMID:11305285
reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At puberty, affected girls have hypergonadotropic hypogonadism, fail to develop secondary sexual characteristics, and exhibit progressive virilization."
explanation: >-
Directly supports hypergonadotropic hypogonadism at puberty in affected
girls.
- category: Reproductive
name: Primary Amenorrhea
description: >-
Absence of menarche due to estrogen deficiency preventing normal pubertal
and endometrial development.
notes: In 46,XX individuals.
phenotype_term:
preferred_term: Primary amenorrhea
term:
id: HP:0000786
label: Primary amenorrhea
evidence:
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At puberty they show primary amenorrhea, no breast development, worsening of the virilization and the absence of growth spurt."
explanation: >-
Directly supports primary amenorrhea in affected females at puberty.
- category: Reproductive
name: Polycystic Ovaries
description: >-
Multiple ovarian cysts associated with elevated gonadotropins and ovarian
androgen excess in 46,XX aromatase deficiency.
frequency: FREQUENT
notes: In 46,XX individuals.
phenotype_term:
preferred_term: Polycystic ovaries
term:
id: HP:0000147
label: Polycystic ovaries
evidence:
- reference: PMID:32623730
reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
explanation: >-
The 13/30 ovarian-cyst frequency supports the FREQUENT band.
- category: Musculoskeletal
name: Delayed Skeletal Maturation
description: >-
Delayed bone age and persistent open epiphyses due to insufficient
estrogen-mediated skeletal maturation.
phenotype_term:
preferred_term: Delayed skeletal maturation
term:
id: HP:0002750
label: Delayed skeletal maturation
evidence:
- reference: PMID:32623730
reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
explanation: >-
Systematic-review data support delayed bone age as a frequent skeletal
finding.
- category: Musculoskeletal
name: Tall Stature
description: >-
Continued linear growth beyond the usual age of epiphyseal closure,
especially in 46,XY affected individuals.
phenotype_term:
preferred_term: Tall stature
term:
id: HP:0000098
label: Tall stature
evidence:
- reference: PMID:11305285
reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "These men are extremely tall and have eunuchoid proportions with continued linear growth into adulthood, lack of epiphyseal closure, and osteoporosis due to estrogen deficiency."
explanation: >-
Directly supports tall stature from continued linear growth in
aromatase-deficient men.
- category: Musculoskeletal
name: Osteoporosis
description: >-
Reduced bone mineral density and increased fracture risk resulting from
inadequate estrogen-mediated bone remodeling and peak bone mass accrual.
frequency: FREQUENT
phenotype_term:
preferred_term: Osteoporosis
term:
id: HP:0000939
label: Osteoporosis
evidence:
- reference: PMID:32623730
reference_title: "Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The main characteristics were maternal antenatal virilization (21/29), ambiguous genitalia (mainly Prader IV or III, 19/23), delayed bone age (16/17), low bone mass (5/8), markedly elevated FSH levels and ovarian cysts (13/30)."
explanation: >-
The 5/8 low-bone-mass count supports a frequent skeletal bone-density
phenotype in reported 46,XX cases with bone-mass data.
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The clinical phenotype in the male affected subjects comprises tall stature, persistent linear growth and delayed bone age, osteopenia/osteoporosis, eunuchoid body proportion, different degrees of glucose-insulin and of fertility impairment.
explanation: >-
Review-level human evidence supports osteopenia/osteoporosis in affected
males.
- category: Metabolic
name: Insulin Resistance
description: >-
Reduced insulin sensitivity or glucose-insulin impairment associated with
congenital estrogen deficiency.
phenotype_term:
preferred_term: Insulin resistance
term:
id: HP:0000855
label: Insulin resistance
evidence:
- reference: PMID:19844120
reference_title: "Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Insulin sensitivity may be abnormal in both men and women."
explanation: >-
Supports abnormal insulin sensitivity as a metabolic manifestation.
genetic:
- name: CYP19A1
gene_term:
preferred_term: CYP19A1
term:
id: hgnc:2594
label: CYP19A1
association: Causative
notes: >-
Biallelic loss-of-function variants in CYP19A1, which encodes aromatase,
cause autosomal recessive aromatase deficiency.
inheritance:
- name: Autosomal recessive
inheritance_term:
preferred_term: Autosomal recessive inheritance
term:
id: HP:0000007
label: Autosomal recessive inheritance
evidence:
- reference: PMID:35837780
reference_title: "Aromatase deficiency caused by mutation of CYP19A1 gene: A case report."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Aromatase deficiency (AD) is a rare autosomal recessive genetic disease caused by loss-of-function mutations in aromatase gene (CYP19A1), leading to congenital estrogen deficiency syndrome.
explanation: >-
Supports autosomal recessive inheritance of CYP19A1 loss-of-function
variants.
evidence:
- reference: PMID:40321354
reference_title: "Aromatase deficiency due to novel CYP19A1 mutation: a rare cause of maternal and fetal virilization."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Aromatase deficiency is a rare autosomal recessive condition due to a mutation in the CYP19A1 encoding aromatase enzyme."
explanation: >-
Confirms CYP19A1 variants as the cause of aromatase deficiency.
- reference: PMID:34348419
reference_title: "Aromatase deficiency in an Ontario Old Order Mennonite family."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our proband is an Old Order Mennonite female born with ambiguous genitalia who was identified to carry novel homozygous variant in the CYP19A1 gene c.1304G>A (p. Arg435His)."
explanation: >-
Reports a homozygous CYP19A1 variant in an affected individual.
biochemical:
- name: Serum Estradiol
presence: DECREASED
context: >-
Estradiol is very low or undetectable because aromatase cannot efficiently
convert androgens to estrogens.
biomarker_term:
preferred_term: estradiol
term:
id: CHEBI:23965
label: estradiol
readouts:
- target: CYP19A1 Loss-of-Function and Aromatase Deficiency
relationship: READOUT_OF
direction: NEGATIVE
endpoint_context: DIAGNOSTIC
interpretation: Very low or undetectable estradiol reports the aromatase enzyme block.
- target: Estrogen Deficiency and Androgen Excess
relationship: READOUT_OF
direction: NEGATIVE
endpoint_context: DIAGNOSTIC
interpretation: Low serum estradiol directly reports the estrogen-deficient endocrine state.
evidence:
- reference: PMID:35837780
reference_title: "Aromatase deficiency caused by mutation of CYP19A1 gene: A case report."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
His estradiol was below the measurable line, the follicle-stimulating hormone (FSH) increased, bone age delayed, epiphysis unfused, and the bone mass reduced.
explanation: >-
Human case report supports very low estradiol with elevated FSH and
skeletal findings.
- reference: PMID:19707181
reference_title: "Aromatase deficiency in men: a clinical perspective."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diagnosis of the condition is supported by the presence of unfused epiphyses and undetectable serum estradiol levels; the condition can be further substantiated by genetic sequencing of CYP19A1."
explanation: >-
Review-level clinical guidance supports undetectable serum estradiol as a
diagnostic biochemical feature.
- name: Serum Testosterone
presence: INCREASED
context: >-
Testosterone is normal to elevated because androgen precursors are not
efficiently aromatized to estrogens.
biomarker_term:
preferred_term: testosterone
term:
id: CHEBI:17347
label: testosterone
readouts:
- target: Estrogen Deficiency and Androgen Excess
relationship: READOUT_OF
direction: POSITIVE
endpoint_context: DIAGNOSTIC
interpretation: Normal-to-elevated circulating testosterone reports androgen excess from failed aromatization.
evidence:
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated.
explanation: >-
Supports normal-to-elevated testosterone in aromatase deficiency.
diagnosis:
- name: CYP19A1 Sequencing and Endocrine Profile
description: >-
Diagnosis is supported by low or undetectable estradiol, elevated
gonadotropins or androgen excess depending on age and sex, and confirmation
by CYP19A1 sequencing.
presence: Positive in affected individuals
evidence:
- reference: PMID:19707181
reference_title: "Aromatase deficiency in men: a clinical perspective."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diagnosis of the condition is supported by the presence of unfused epiphyses and undetectable serum estradiol levels; the condition can be further substantiated by genetic sequencing of CYP19A1."
explanation: >-
Supports the combined biochemical, skeletal, and genetic diagnostic
approach.
- reference: PMID:25415177
reference_title: "Five new cases of 46,XX aromatase deficiency: clinical follow-up from birth to puberty, a novel mutation, and a founder effect."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Direct sequencing of the CYP19A1 gene from genomic DNA revealed one novel mutation (c.574C>T) in two patients."
explanation: >-
Demonstrates diagnostic CYP19A1 sequencing in affected 46,XX patients.
treatments:
- name: Estrogen Replacement Therapy
description: >-
Estradiol replacement restores estrogen exposure, supports skeletal
maturation and epiphyseal closure, and is the central disease-directed
therapy once aromatase deficiency is diagnosed.
treatment_term:
preferred_term: hormone modifying therapy
description: Therapeutic administration of estrogen to replace deficient endogenous hormone production.
term:
id: MAXO:0000283
label: hormone modifying therapy
therapeutic_agent:
- preferred_term: estradiol
term:
id: CHEBI:23965
label: estradiol
evidence:
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation."
explanation: >-
Supports estradiol replacement as disease-directed therapy for skeletal
maturation.
- reference: PMID:19707181
reference_title: "Aromatase deficiency in men: a clinical perspective."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Transdermal estradiol treatment at a daily dose of about 25 microg might be adequate for lifelong replacement therapy."
explanation: >-
Clinical review supports lifelong estradiol replacement therapy in
affected males.
target_mechanisms:
- target: Estrogen Deficiency and Androgen Excess
treatment_effect: RESTORES
description: Estradiol replacement restores downstream estrogen exposure despite persistent CYP19A1 deficiency.
evidence:
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation."
explanation: >-
Clinical response to estradiol replacement supports restoration of
estrogen-dependent downstream physiology.
- target: Impaired Skeletal Maturation and Bone Remodeling
treatment_effect: RESTORES
description: Estradiol replacement promotes epiphyseal closure and skeletal maturation.
evidence:
- reference: PMID:18448329
reference_title: "Human models of aromatase deficiency."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation."
explanation: >-
Directly supports restoration of skeletal maturation with estradiol
replacement.
Disease Pathophysiology Research Report
Target Disease - Disease Name: Aromatase Deficiency (CYP19A1 loss-of-function) - MONDO ID: MONDO:0009735 (Aromatase deficiency; if subtyping required, consult ontology updates) - Category: Genetic (autosomal recessive disorder of steroidogenesis)
Pathophysiology description Aromatase deficiency is caused by biallelic pathogenic variants in CYP19A1 encoding microsomal aromatase (P450 19A1), the enzyme that converts C19 androgens (androstenedione, testosterone, 16α‑OH‑DHEA) into C18 estrogens (estrone, estradiol, estriol). Placental, gonadal, adipose, bone, brain, and other tissue expression means loss of aromatase produces systemic estrogen deficiency with accumulation of androgens. In pregnancy, failure of placental aromatase prevents conversion of fetal adrenal precursors (notably 16‑OH‑DHEAS) to estriol, allowing maternal exposure to androgen excess and leading to maternal virilization; concurrently, female (46,XX) fetuses are virilized by excess androgens. Core downstream effects include disruption of estrogen receptor signaling (ESR1/ESR2/GPER), disinhibited hypothalamic–pituitary–gonadal (HPG) axis drive (hypergonadotropic hypogonadism), impaired bone maturation and remodeling (delayed epiphyseal fusion, low bone mass), and adverse metabolic profiles (insulin resistance, dyslipidemia). “Pathogenic variants in the CYP19A1 gene lead to aromatase deficiency, causing androgen excess,” and placental/fetal aromatase normally “protects the mother from virilization” by metabolizing fetal androgens; deficiency therefore causes maternal and fetal virilization with very low estrogens and elevated androgens (46,XX DSD) (abalı2024diagnosisandmanagement pages 1-2, abalı2024diagnosisandmanagement pages 4-5, stancampiano202446xxdifferencesof pages 8-9). The clinical physiology of complete aromatase loss includes 46,XX ambiguous genitalia at birth, progressive virilization, and in both sexes estrogen‑dependent bone effects such as “delayed epiphyseal closure and osteopenia/osteoporosis,” with tall stature described in males due to unfused epiphyses (blakemore2016aromatasecontributionsto pages 5-7).
Core Pathophysiology - Primary mechanisms: loss of aromatase-mediated androgen→estrogen conversion; prenatal placental failure of estriol synthesis; systemic estrogen deficiency with androgen excess (stancampiano202446xxdifferencesof pages 8-9, abalı2024diagnosisandmanagement pages 1-2). - Dysregulated pathways: steroidogenesis flux (C19 accumulation), estrogen receptor signaling (ESR1/ESR2/GPER), HPG feedback (↑LH/FSH from low estrogen), bone remodeling (↑RANKL signaling with hypoestrogenism), metabolic regulation (insulin sensitivity, lipid homeostasis) (blakemore2016aromatasecontributionsto pages 5-7, abalı2024diagnosisandmanagement pages 5-6). - Affected cellular processes: ER-resident P450 catalysis; ligand-activated transcription via nuclear ERs; membrane-initiated estrogen signaling; endochondral ossification and growth plate fusion; ovarian folliculogenesis dependent on granulosa aromatase (blakemore2016aromatasecontributionsto pages 5-7, stancampiano202446xxdifferencesof pages 8-9).
Key Molecular Players - Genes/Proteins (HGNC): CYP19A1/AROMATASE (HGNC:2594) causal; ERs ESR1 (HGNC:3467), ESR2 (HGNC:3468) and GPER1 (HGNC:4485) as signaling mediators; POR (HGNC:9208) as differential diagnosis affecting multiple microsomal P450s including CYP19A1; NR5A1 (HGNC:2510) may modify DSD phenotypes but is not causal in AroD (abalı2024diagnosisandmanagement pages 4-5, stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7). - Chemical entities (CHEBI): androgens (androstenedione CHEBI:28689; testosterone CHEBI:17347) accumulate; estrogens (estrone CHEBI:17263; estradiol CHEBI:16469; estriol CHEBI:16490) are reduced; fetal precursor DHEA-S (CHEBI:28941) normally feeds placental estriol synthesis; antiandrogens (flutamide CHEBI:5102; spironolactone CHEBI:9606) are used adjunctively (stancampiano202446xxdifferencesof pages 8-9, abalı2024diagnosisandmanagement pages 1-2). - Cell types (CL): granulosa cells (ovarian estrogen synthesis); trophoblast (placental aromatase and maternal protection); Leydig cells (androgen production); osteoblasts/osteoclasts (bone remodeling under estrogen control); adipocytes (peripheral aromatization) (stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7). - Anatomical locations (UBERON): ovary, placenta, uterus, testis, bone, adipose tissue, brain are key affected sites (stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7).
Biological Processes (GO) - Steroid biosynthetic process (GO:0006694); estrogen biosynthetic process (GO:0006703) directly impaired by CYP19A1 loss (stancampiano202446xxdifferencesof pages 8-9). - Androgen metabolic process (GO:0008209) with accumulation of C19 substrates (abalı2024diagnosisandmanagement pages 1-2). - Estrogen receptor signaling pathway (GO:0030520) diminished systemically (blakemore2016aromatasecontributionsto pages 5-7). - Regulation of gonadotropin secretion (GO:0032274) disrupted, producing hypergonadotropic hypogonadism (blakemore2016aromatasecontributionsto pages 5-7). - Bone remodeling (GO:0046849) and endochondral ossification (GO:0001958) altered with delayed epiphyseal closure (blakemore2016aromatasecontributionsto pages 5-7).
Cellular Components - Endoplasmic reticulum membrane (GO:0005789) and microsomes (GO:0005792) host aromatase catalysis; estrogen receptors act at plasma membrane (GPER1) and nucleus (ESR1/ESR2), with systemic effects mediated via the extracellular hormone milieu (GO:0005886, GO:0005634, GO:0005615) (stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7).
Disease Progression - Fetal: placental aromatase failure → maternal virilization in pregnancy; 46,XX fetal virilization due to transplacental and fetal androgen excess; estriol production markedly reduced (stancampiano202446xxdifferencesof pages 8-9, abalı2024diagnosisandmanagement pages 1-2). - Neonatal/Childhood: 46,XX ambiguous genitalia (clitoromegaly, posterior labial fusion, urogenital sinus); elevated androgens, very low estrogens; ovarian changes may include enlarged/multicystic or hypoplastic ovaries (abalı2024diagnosisandmanagement pages 5-6). - Puberty: hypergonadotropic hypogonadism with delayed/absent thelarche; progressive virilization if untreated; residual activity variants may show partial breast development (abalı2024diagnosisandmanagement pages 5-6). - Adulthood: fertility impairment in 46,XX; bone health complications (low BMD, delayed epiphyseal closure); metabolic features (insulin resistance, dyslipidemia) (blakemore2016aromatasecontributionsto pages 5-7, abalı2024diagnosisandmanagement pages 5-6).
Phenotypic Manifestations - 46,XX: prenatal virilization with ambiguous genitalia; pubertal failure with amenorrhea and hypergonadotropic hypogonadism; ovarian macrocysts or multicystic ovaries; progressive virilization; reduced estradiol with elevated androgens (abalı2024diagnosisandmanagement pages 5-6, abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9). - 46,XY: external genitalia typically normal or mildly affected; prominent estrogen-deficiency skeletal findings (tall stature, delayed epiphyseal closure, osteopenia/osteoporosis), reduced libido; metabolic derangements (blakemore2016aromatasecontributionsto pages 5-7).
Current applications and real-world implementations - Diagnostics: LC–MS/MS steroid profiling to demonstrate elevated C19 androgens with very low estrogens; genetic testing via targeted CYP19A1 sequencing or exome/genome sequencing; crucial differential diagnosis with POR deficiency (which reduces CYP19A1 activity secondarily) using gene testing and distinctive steroid profiles; prenatal suspicion with maternal virilization and low estriol (abalı2024diagnosisandmanagement pages 4-5, abalı2024diagnosisandmanagement pages 1-2). - Management: estrogen replacement therapy for pubertal induction and maintenance in 46,XX; consider antiandrogens (e.g., flutamide, spironolactone) to mitigate virilization; monitor and treat bone health in both sexes; fertility management is individualized, with limited long-term outcome data (abalı2024diagnosisandmanagement pages 5-6, blakemore2016aromatasecontributionsto pages 5-7). Expert reviews emphasize that estrogen replacement can improve ovarian phenotype (e.g., cyst resolution) and hypogonadism, though evidence remains from case-level data (abalı2024diagnosisandmanagement pages 5-6).
Expert opinions and recent developments (2023–2024) - 2024 DSD reviews place aromatase deficiency among non-CAH 46,XX DSD etiologies and stress advances in cytogenetic and molecular diagnostics; they reaffirm that “Pathogenic variants in the CYP19A1 gene lead to aromatase deficiency, causing androgen excess,” and that prenatal-onset androgen excess drives the 46,XX phenotype, with management challenges persisting due to rarity and heterogeneity (published 15 May 2024; Frontiers in Endocrinology; https://doi.org/10.3389/fendo.2024.1354759) (abalı2024diagnosisandmanagement pages 1-2). - A 2024 review of 46,XX DSDs outside CAH summarizes CYP19A1 genetics, tissue-specific expression, and placental metabolism of fetal 16‑OH‑DHEAS to estriol, underscoring the mechanistic basis of maternal/fetal virilization in aromatase deficiency (published May 2024; Frontiers in Endocrinology; https://doi.org/10.3389/fendo.2024.1402579) (stancampiano202446xxdifferencesof pages 8-9). - Differential with POR deficiency (2023 review) remains clinically salient since POR defects can cause “placental aromatase deficiency affected by POR,” necessitating distinct management pathways (published Aug 2023; Frontiers in Endocrinology; https://doi.org/10.3389/fendo.2023.1226387) (abalı2024diagnosisandmanagement pages 4-5). - Foundational expert synthesis (Physiology 2016) continues to frame the phenotype spectrum and systemic estrogen roles in bone and metabolism, with quotations widely cited in current reviews for skeletal and metabolic consequences of aromatase loss (published Jul 2016; https://doi.org/10.1152/physiol.00054.2015) (blakemore2016aromatasecontributionsto pages 5-7).
Relevant statistics and data - Case accrual remains limited; a 2024 review cites approximately 40 reported cases since the first description in 1991, reflecting the rarity of confirmed CYP19A1 biallelic loss-of-function (published May 2024) (stancampiano202446xxdifferencesof pages 8-9). - Biochemical hallmarks summarized in recent reviews include “elevated plasma androstenedione and testosterone with very low or undetectable estrone/estradiol,” consistent across reported cases (abalı2024diagnosisandmanagement pages 5-6).
Direct quotes supporting key statements - “Pathogenic variants in the CYP19A1 gene lead to aromatase deficiency, causing androgen excess.” (Frontiers in Endocrinology, 15 May 2024; https://doi.org/10.3389/fendo.2024.1354759) (abalı2024diagnosisandmanagement pages 1-2). - Placental aromatase “protects the mother from virilization,” so deficiency leads to maternal and fetal virilization (summarized in 2024 reviews) (abalı2024diagnosisandmanagement pages 4-5, stancampiano202446xxdifferencesof pages 8-9). - Clinical physiology includes “delayed epiphyseal closure and osteopenia/osteoporosis” with tall stature in males (Physiology, Jul 2016; https://doi.org/10.1152/physiol.00054.2015) (blakemore2016aromatasecontributionsto pages 5-7).
Gene/protein annotations with ontology terms - CYP19A1 (HGNC:2594): aromatase, ER membrane P450; GO:0006703, GO:0006694; components GO:0005789/GO:0005792 (stancampiano202446xxdifferencesof pages 8-9). - ESR1 (HGNC:3467), ESR2 (HGNC:3468), GPER1 (HGNC:4485): estrogen signaling; GO:0030520; nucleus GO:0005634; plasma membrane GO:0005886 (blakemore2016aromatasecontributionsto pages 5-7). - POR (HGNC:9208): electron donor to microsomal CYPs; differential that can mimic aromatase deficiency (abalı2024diagnosisandmanagement pages 4-5).
Phenotype associations (HP terms) - Ambiguous genitalia (HP:0000062), clitoromegaly (HP:0008665), primary amenorrhea (HP:0000786), hypergonadotropic hypogonadism (HP:0000045), ovarian cyst (HP:0000137), tall stature (HP:0000098), delayed epiphyseal closure (HP:0003070), osteoporosis (HP:0000939), insulin resistance (HP:0000855), dyslipidemia (HP:0003119) (abalı2024diagnosisandmanagement pages 5-6, blakemore2016aromatasecontributionsto pages 5-7, stancampiano202446xxdifferencesof pages 8-9).
Cell type involvement (CL terms) - Granulosa cell (CL:0002320), trophoblast (CL:0000351), Leydig cell (CL:0000182), osteoblast (CL:0000062), osteoclast (CL:0000092), adipocyte (CL:0000136) (stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7).
Anatomical locations (UBERON terms) - Ovary (UBERON:0000992), placenta (UBERON:0001987), uterus (UBERON:0000995), testis (UBERON:0000473), bone (UBERON:0001474), adipose (UBERON:0001013), brain (UBERON:0000955) (stancampiano202446xxdifferencesof pages 8-9, blakemore2016aromatasecontributionsto pages 5-7).
Chemical entities (CHEBI terms) - Androstenedione (CHEBI:28689), testosterone (CHEBI:17347), estrone (CHEBI:17263), estradiol (CHEBI:16469), estriol (CHEBI:16490), DHEA sulfate (CHEBI:28941), spironolactone (CHEBI:9606), flutamide (CHEBI:5102) (stancampiano202446xxdifferencesof pages 8-9, abalı2024diagnosisandmanagement pages 1-2).
Embedded artifact | Category | Item (name) | Ontology ID | Notes on role in disease | |---|---|---:|---| | Gene / Protein | CYP19A1 | HGNC:2594 | Aromatase enzyme; loss causes androgen accumulation and estrogen deficiency. (abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9) | | Gene / Protein | ESR1 | HGNC:3467 | Estrogen receptor alpha mediates estrogen signaling; affected by low estrogen. (blakemore2016aromatasecontributionsto pages 5-7) | | Gene / Protein | ESR2 | HGNC:3468 | Estrogen receptor beta; tissue-specific estrogen responses diminished. (blakemore2016aromatasecontributionsto pages 5-7) | | Gene / Protein | GPER1 | HGNC:4485 | Membrane estrogen receptor mediating rapid signaling; hypoestrogenism reduces activity. (blakemore2016aromatasecontributionsto pages 5-7) | | Gene / Protein | NR5A1 | HGNC:2510 | Transcription factor in gonadal development; can modify DSD phenotypes. (stancampiano202446xxdifferencesof pages 8-9) | | Gene / Protein | POR | HGNC:9208 | Electron donor to microsomal CYPs; POR defects can phenocopy aromatase issues. (abalı2024diagnosisandmanagement pages 4-5, stancampiano202446xxdifferencesof pages 8-9) | | Cell type | Granulosa cell | CL:0002320 | Site of ovarian aromatase expression; estrogen synthesis is impaired. (stancampiano202446xxdifferencesof pages 8-9) | | Cell type | Trophoblast | CL:0000351 | Placental aromatase site; loss causes maternal and fetal virilization. (abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9) | | Cell type | Leydig cell | CL:0000182 | Testicular androgen source; peripheral aromatization affects systemic balance. (blakemore2016aromatasecontributionsto pages 5-7) | | Cell type | Osteoblast | CL:0000062 | Bone-forming cell; estrogen deficiency increases bone resorption risk. (blakemore2016aromatasecontributionsto pages 5-7) | | Cell type | Osteoclast | CL:0000092 | Bone-resorbing cell; activity increases when estrogen is low. (blakemore2016aromatasecontributionsto pages 5-7) | | Cell type | Adipocyte | CL:0000136 | Peripheral aromatase expression site; contributes to local estrogen production. (blakemore2016aromatasecontributionsto pages 5-7, stancampiano202446xxdifferencesof pages 8-9) | | Anatomical location | Ovary | UBERON:0000992 | Site of granulosa aromatase; ovarian development and fertility impacted. (stancampiano202446xxdifferencesof pages 8-9) | | Anatomical location | Placenta | UBERON:0001987 | Crucial for fetal estrogen production; maternal virilization if deficient. (abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9) | | Anatomical location | Uterus | UBERON:0000995 | Estrogen-dependent organ; hypoplasia and poor endometrial development possible. (blakemore2016aromatasecontributionsto pages 5-7) | | Anatomical location | Testis | UBERON:0000473 | Androgen source; 46,XY genital phenotype often milder than 46,XX. (blakemore2016aromatasecontributionsto pages 5-7) | | Anatomical location | Bone | UBERON:0001474 | Affected by estrogen deficiency causing delayed epiphyseal closure and osteopenia. (blakemore2016aromatasecontributionsto pages 5-7) | | Anatomical location | Adipose tissue | UBERON:0001013 | Expresses aromatase; loss alters metabolic regulation and lipid profiles. (blakemore2016aromatasecontributionsto pages 5-7) | | Anatomical location | Brain | UBERON:0000955 | Central estrogen actions on behavior and HPG axis signaling disrupted. (blakemore2016aromatasecontributionsto pages 5-7) | | Biological process | Steroid biosynthetic process | GO:0006694 | Overall steroidogenesis altered with accumulation of androgens. (stancampiano202446xxdifferencesof pages 8-9) | | Biological process | Estrogen biosynthetic process | GO:0006703 | Aromatase-catalyzed estrogen synthesis is impaired. (stancampiano202446xxdifferencesof pages 8-9) | | Biological process | Androgen metabolic process | GO:0008209 | Androgen metabolism shifts toward accumulation of C19 steroids. (abalı2024diagnosisandmanagement pages 1-2) | | Biological process | Estrogen receptor signaling pathway | GO:0030520 | Downstream estrogen signaling reduced, affecting multiple tissues. (blakemore2016aromatasecontributionsto pages 5-7) | | Biological process | Regulation of gonadotropin secretion | GO:0032274 | HPG feedback disrupted causing hypergonadotropic hypogonadism. (blakemore2016aromatasecontributionsto pages 5-7) | | Biological process | Bone remodeling | GO:0046849 | Imbalanced osteoblast/osteoclast activity leading to bone loss. (blakemore2016aromatasecontributionsto pages 5-7) | | Biological process | Endochondral ossification | GO:0001958 | Delayed epiphyseal closure due to low estrogen levels. (blakemore2016aromatasecontributionsto pages 5-7) | | Cellular component | Endoplasmic reticulum membrane | GO:0005789 | Location of microsomal aromatase P450 enzyme. (stancampiano202446xxdifferencesof pages 8-9) | | Cellular component | Microsome | GO:0005792 | Subcellular fraction containing aromatase activity. (stancampiano202446xxdifferencesof pages 8-9) | | Cellular component | Plasma membrane | GO:0005886 | Location of membrane estrogen receptor GPER; signaling changes. (blakemore2016aromatasecontributionsto pages 5-7) | | Cellular component | Nucleus | GO:0005634 | Nuclear ER-mediated transcriptional responses are impaired. (blakemore2016aromatasecontributionsto pages 5-7) | | Cellular component | Extracellular space | GO:0005615 | Circulating steroid hormones and paracrine signaling altered. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Androstenedione | CHEBI:28689 | Major aromatase substrate; accumulates when enzyme deficient. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Testosterone | CHEBI:17347 | Substrate and androgenic effector causing virilization. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Estrone | CHEBI:17263 | Estrogen product reduced leading to systemic hypoestrogenism. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Estradiol | CHEBI:16469 | Primary active estrogen decreased causing multisystem effects. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Estriol | CHEBI:16490 | Placental fetal estrogen reduced; derived from 16OH-DHEAS normally. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | DHEA sulfate | CHEBI:28941 | Fetal adrenal precursor feeding placental estrogen synthesis; altered flux. (stancampiano202446xxdifferencesof pages 8-9) | | Chemical entity | Spironolactone | CHEBI:9606 | Anti-androgen sometimes used to reduce virilization (off-label). (abalı2024diagnosisandmanagement pages 1-2) | | Chemical entity | Flutamide | CHEBI:5102 | Androgen receptor antagonist used to counter virilization. (abalı2024diagnosisandmanagement pages 1-2) | | Phenotype | Ambiguous genitalia | HP:0000062 | 46,XX virilization leading to atypical external genitalia. (abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9) | | Phenotype | Clitoromegaly | HP:0008665 | Enlarged clitoris due to prenatal androgen exposure. (abalı2024diagnosisandmanagement pages 1-2) | | Phenotype | Primary amenorrhea | HP:0000786 | Absent menses from hypergonadotropic hypogonadism. (abalı2024diagnosisandmanagement pages 1-2, blakemore2016aromatasecontributionsto pages 5-7) | | Phenotype | Hypergonadotropic hypogonadism | HP:0000045 | Elevated gonadotropins due to low estrogen negative feedback. (blakemore2016aromatasecontributionsto pages 5-7) | | Phenotype | Ovarian cyst | HP:0000137 | Multicystic ovaries reported from unopposed gonadotropin stimulation. (abalı2024diagnosisandmanagement pages 4-5, stancampiano202446xxdifferencesof pages 8-9) | | Phenotype | Tall stature | HP:0000098 | Delayed epiphyseal closure results in increased final height. (blakemore2016aromatasecontributionsto pages 5-7) | | Phenotype | Delayed epiphyseal closure | HP:0003070 | Result of estrogen deficiency impairing growth plate fusion. (blakemore2016aromatasecontributionsto pages 5-7) | | Phenotype | Osteoporosis | HP:0000939 | Low bone mass risk due to chronic hypoestrogenism. (blakemore2016aromatasecontributionsto pages 5-7) | | Phenotype | Insulin resistance | HP:0000855 | Metabolic alterations including insulin resistance reported. (abalı2024diagnosisandmanagement pages 5-6, stancampiano202446xxdifferencesof pages 8-9) | | Phenotype | Dyslipidemia | HP:0003119 | Adverse lipid profile associated with low aromatase activity. (blakemore2016aromatasecontributionsto pages 5-7) |
Table: Compact ontology table mapping key genes, cells, locations, processes, components, chemicals, and phenotypes relevant to aromatase (CYP19A1) deficiency, with concise functional notes and source citations for database use.
Evidence items (PMIDs/DOIs/URLs; publication dates) - Abalı ZY, Guran T. Diagnosis and management of non-CAH 46,XX DSD. Frontiers in Endocrinology. Published 15 May 2024. DOI: 10.3389/fendo.2024.1354759. URL: https://doi.org/10.3389/fendo.2024.1354759 (abalı2024diagnosisandmanagement pages 1-2). - Stancampiano MR, et al. 46,XX DSD outside CAH. Frontiers in Endocrinology. Published May 2024. DOI: 10.3389/fendo.2024.1402579. URL: https://doi.org/10.3389/fendo.2024.1402579 (stancampiano202446xxdifferencesof pages 8-9). - Wang C, Tian Q. POR deficiency review. Frontiers in Endocrinology. Published Aug 2023. DOI: 10.3389/fendo.2023.1226387. URL: https://doi.org/10.3389/fendo.2023.1226387 (abalı2024diagnosisandmanagement pages 4-5). - Blakemore J, Naftolin F. Aromatase: physiology and disease. Physiology. Published Jul 2016. DOI: 10.1152/physiol.00054.2015. URL: https://doi.org/10.1152/physiol.00054.2015 (blakemore2016aromatasecontributionsto pages 5-7).
Limitations and open questions The rarity of confirmed CYP19A1 biallelic cases limits robust natural history and interventional evidence; many management suggestions derive from small series and case reports. Contemporary reviews call for standardized diagnostic algorithms (LC–MS/MS, genomics) and longitudinal registries to clarify fertility outcomes and optimal timing/dosing of estrogen therapy (abalı2024diagnosisandmanagement pages 1-2, stancampiano202446xxdifferencesof pages 8-9).
References
(abalı2024diagnosisandmanagement pages 1-2): Zehra Yavas Abalı and Tulay Guran. Diagnosis and management of non-cah 46,xx disorders/differences in sex development. Frontiers in Endocrinology, May 2024. URL: https://doi.org/10.3389/fendo.2024.1354759, doi:10.3389/fendo.2024.1354759. This article has 10 citations and is from a poor quality or predatory journal.
(abalı2024diagnosisandmanagement pages 4-5): Zehra Yavas Abalı and Tulay Guran. Diagnosis and management of non-cah 46,xx disorders/differences in sex development. Frontiers in Endocrinology, May 2024. URL: https://doi.org/10.3389/fendo.2024.1354759, doi:10.3389/fendo.2024.1354759. This article has 10 citations and is from a poor quality or predatory journal.
(stancampiano202446xxdifferencesof pages 8-9): Marianna Rita Stancampiano, Silvia Laura Carla Meroni, Carmen Bucolo, and Gianni Russo. 46,xx differences of sex development outside congenital adrenal hyperplasia: pathogenesis, clinical aspects, puberty, sex hormone replacement therapy and fertility outcomes. Frontiers in Endocrinology, May 2024. URL: https://doi.org/10.3389/fendo.2024.1402579, doi:10.3389/fendo.2024.1402579. This article has 8 citations and is from a poor quality or predatory journal.
(blakemore2016aromatasecontributionsto pages 5-7): Jennifer Blakemore and Fredrick Naftolin. Aromatase: contributions to physiology and disease in women and men. Physiology, 31 4:258-69, Jul 2016. URL: https://doi.org/10.1152/physiol.00054.2015, doi:10.1152/physiol.00054.2015. This article has 240 citations and is from a peer-reviewed journal.
(abalı2024diagnosisandmanagement pages 5-6): Zehra Yavas Abalı and Tulay Guran. Diagnosis and management of non-cah 46,xx disorders/differences in sex development. Frontiers in Endocrinology, May 2024. URL: https://doi.org/10.3389/fendo.2024.1354759, doi:10.3389/fendo.2024.1354759. This article has 10 citations and is from a poor quality or predatory journal.